AI newco Envisagenics raises $2.4M in seed round

Envisagenics Inc. (New York, N.Y.) raised $2.4 million in a seed round. Third Kind Venture Capital, Cosine LLC, Dolby Family Ventures, Dynamk Capital, NY Empire State Development, and SV Angel participated.

In October, the artificial intelligence company launched SpliceCore, its only commercial product. The cloud-based platform is designed to predict drug targets and biomarkers by applying AI to RNA sequencing data. The company plans to use the technology to identify new splicing errors and targets in cancers and genetic diseases, and develop RNA therapeutics through partnerships and collaborations...